Selective biopsy of the sentinel node in cancer of cervix: Experience in validation phase. / Biopsia selectiva del ganglio centinela en cáncer de cérvix: experiencia en fase de validación.

BACKGROUND AND OBJECTIVE: Sentinel lymph node biopsy (SLNB) was created to reduce the morbidity associated with pelvic lymphadenectomy in the early stages of cervical cancer (CC), preserving its prognostic information. The goal is to assess the diagnostic validity of SLNB in CC in initial stages (IA1 with lymphovascular infiltration (LVI) +, IA2, IB1 and IIA1), thus avoiding unnecessary lymphadenectomies in many of the cases. MATERIAL AND METHOD: From January 2012 to April 2017, 23 patients with initial stages of CC were included in a cross-sectional study to evaluate the effectiveness of the SLNB in CC with a mixed technique of cervical injection of 99mTc-nanocolloid of albumin and methylene blue, using combined planar lymphoscintigraphy with multimodality SPECT/CT image and subsequent removal of the sentinel node (SN) by laparoscopy. RESULTS: The detection rate of SLNB with the mixed technique was 95.65%, with a negative predictive value (NPV) of 95.45% and sensitivity (S) of 100% in the case of bilateral drainage. The mean of excised SN was 3 (range 1-5). The bilateral detection rate in laparoscopy was 85.35%. The concordance between SPECT/CT and laparoscopy for the number and bilaterality of the SN using the Pearson coefficient was r = 0.727 and r = 0.833, respectively; p = 0.01. We only found one SN with a deferred result of micrometástasis and one false negative was detected. CONCLUSIONS: SLNB in CC using a mixed technique has a high detection and bilateral drainage rate, but S is still low if we include cases of unilateral drainage. A greater number of cases and the development of intraoperative ultrastaging could increase the S of the technique and to reduce the number of false negatives.

Teratoma ovárico maduro e inmaduro, a propósito de un caso / About a case of mature and immature ovarian teratoma

Resumen: CASO CLÍNICO: paciente de 30 años de edad, con diagnóstico de teratoma inmaduro, con deseos de preservar la fertilidad. Se indicó tratamiento quirúrgico conservador y quimioterapia coadyuvante, previa vitrificación de ovocitos. Un año después de finalizar la quimioterapia logró embarazarse mediante fecundación in vitro, realizada con sus propios óvulos desvitrificados. Después de tres años de la intervención quirúrgica se detectó otro quiste en el ovario contralateral, que se intervino y diagnosticó como teratoma maduro. CONCLUSIONES: el teratoma ovárico inmaduro es una neoplasia poco frecuente cuyo tratamiento aún se discute. Puesto que la mayoría de las pacientes son jóvenes debe intentarse la preservación de la fertilidad proponiéndoles la preservación de ovocitos. Debido a la alta tasa de recurrencia del tumor, casi siempre en forma de teratoma maduro, es importante el seguimiento estrecho después de finalizar el tratamiento.

Abstract: CLINICAL CASE: We present a peculiar case in which an immature teratoma is diagnosed by an ovarian torsion in a 30 year old patient. She wanted to preserve her fertility, so she underwent conservative surgical treatment, previous vitrification of her oocytes. One year after the end of the chemotherapeutic treatment, the patient became pregnant through in vitro fertilization performed with her own devitrified oocytes. Another cyst in the contralateral ovary was diagnosed three years after the surgical intervention so she was reintervenated, it was a mature teratoma. CONCLUSIONS: Immature ovarian teratoma is an uncommon pathology whose treatment is controversial. Since most patients are young, we should try to preserve fertility if the patient wishes, by offering cryopreservation of oocytes when indicated. Due to the high rate of recurrence, often in the form of mature teratoma, it is important to follow-up closely after the treatment.

Favourable response to rituximab by an ocular adnexal primary lymphoma. / Respuesta favorable a rituximab de un linfoma primario de anejos oculares.

CASE REPORT: A 70-year-old woman who presented with an extranodal marginal zone B-cell lymphoma in lacrimal gland and conjunctiva. Initial treatment with rituximab yielded an immediate good response. Five months later she showed lymphoid proliferation in her contralateral conjunctiva. Although no additional treatment was performed, the patient has been free of systemic symptoms and recurrences. DISCUSSION: Rituximab is a quite good therapeutic agent in low grade adnexal lymphomas.